MoonLake Immunotherapeutics MLTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.71M-71.9% | -$63.02M-35.8% | -$70.69M-95.8% | -$56.05M-126% | -$40.56M-190% | ||
| $845K+124% | $751K+106% | $745K+112% | $742K+117% | $378K+15.2% | ||
| $13.36M+483% | $3.59M+85.6% | $3.71M+101% | $3.31M+81.0% | $2.29M+36.6% | ||
| -$6.17M-305% | $4.27M— | $8.2M+47.3% | $5.07M+206% | $3.01M+83.2% | ||
| $7.12M+558% | —— | $12.86M+510% | -$1.81M-207% | -$1.56M+44.6% | ||
| $749K-55.9% | —— | —— | —— | $1.7M— | ||
| -$422K-240% | $92K-80.8% | —— | $1.34M— | -$124K-193% | ||
| $10.1M+3,800% | -$3.86M-172% | -$274K— | $3.84M-53.0% | -$273K-133% | ||
| $11K+375% | -$31K-875% | -$18K-800% | -$5K-400% | -$4K— | ||
| -$389K-52.5% | -$377K+31.6% | -$401K-169% | -$189K+40.4% | -$255K+37.2% | ||
| $894K+512% | $847K+94.3% | $612K-16.2% | $420K+132% | $146K-66.7% | ||
| -$66.29M-73.8% | -$58.79M-21.3% | -$44.54M-76.2% | -$54.53M-95.5% | -$38.14M-155% | ||
| $0-100% | —— | —— | —— | $35K-83.5% | ||
| $59.07M-33.3% | $59.17M-59.7% | $0-100% | $117.66M+36.1% | $88.55M+1.0% | ||
| $59.17M-59.1% | $29.26M— | $88.4M+0.9% | $205.91M— | $144.83M+145% | ||
| $98K-99.8% | —— | $88.4M— | $88.25M+201% | $56.25M+295% | ||
| $24.47M-66.5% | —— | —— | —— | $73.02M— | ||
| $6.01M— | —— | $0-100% | $0— | $0-100% | ||
| $30.64M-58.1% | $72.4M+47,844% | $480K+162% | $0— | $73.12M+43.4% | ||
| -$483K-449% | $91K-78.5% | —— | $1.39M— | -$88K-291% | ||
| -$36.03M-140% | —— | $44.06M— | $35.12M+130% | $91.14M+1,153% | ||
| $1.82M— | $2.19M— | $1.72M— | $1.16M— | $0— | ||
| $7.12M+558% | —— | $12.86M+510% | -$1.81M-207% | -$1.56M+44.6% | ||
| -$389K-52.5% | -$377K+31.6% | -$401K-169% | -$189K+40.4% | -$255K+37.2% | ||
| $30K— | $0-100% | $0— | $0— | $0-100% | ||
| $894K+512% | $847K+94.3% | $612K-16.2% | $420K+132% | $146K-66.7% | ||
| $10.1M+3,800% | -$3.86M-172% | -$274K— | $3.84M-53.0% | -$273K-133% | ||
| -$422K-240% | $92K-80.8% | —— | $1.34M— | -$124K-193% | ||
| $11K+375% | -$31K-875% | -$18K-800% | -$5K-400% | -$4K— | ||
| $59.17M-59.1% | $29.26M— | $88.4M+0.9% | $205.91M— | $144.83M+145% | ||
| -$483K-449% | $91K-78.5% | —— | $1.39M— | -$88K-291% | ||
| -$389K-52.5% | -$377K+31.6% | -$401K-169% | -$189K+40.4% | -$255K+37.2% | ||
| $567K— | $0— | $0-100% | $0— | $0-100% | ||
| -$66.29M-73.6% | -$58.79M-20.9% | -$44.54M-75.3% | -$54.53M-95.5% | -$38.18M-152% | ||
| -$66.29M-73.6% | -$58.79M-20.9% | -$44.54M-75.3% | -$54.53M-95.5% | -$38.18M-152% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does MoonLake Immunotherapeutics's cash flow data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.